Patients with severe asthma who had high levels of fractional exhaled nitric oxide (FeNO) were more likely to have asthma exacerbations than those with low levels.
Spirometry measurements obtained at home had poor agreement with results obtained in the clinic.
Asthma and chronic obstructive pulmonary disease (COPD) do not appear to increase the risk of mortality in patients with COVID-19.
Surgical lung biopsies that are performed via video-assisted thoracic surgery are safe for obtaining histopathologic tissue for select patients.
Single-inhaler triple therapy is associated with a favorable benefit-risk profile compared with dual therapy for patients with symptomatic COPD and a history of exacerbations.
Long-term treatment of oral corticosteroid (OCS)-dependent asthma with dupilumab has shown efficacy in weaning off OCS while improving lung function.
Patients with COPD who exhibit low blood eosinophil counts had no change in exacerbations or survival compared with patients with typical counts.
Patients with lung cancer and poor pulmonary function at diagnosis have worse rates of overall survival.
Use of vasoactive intestinal peptide to treat critical COVID-19 respiratory failure in patients with comorbidities has shown promise.
Both dual bronchodilation and triple therapy demonstrated similar rates of mortality in patients with moderate to severe COPD at low risk for exacerbations.
